|
Jul 22
|
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
|
|
Jul 22
|
Ionis plots next steps for Angelman drug Biogen passed on
|
|
Jul 22
|
Sage Therapeutics/Biogen’s episodic therapy zuranolone could change MDD treatment
|
|
Jul 19
|
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
|
|
Jun 26
|
Pharma M&A: The top high value deals in 2023
|
|
Jun 25
|
Is the Options Market Predicting a Spike in Biogen (BIIB) Stock?
|
|
Jun 24
|
Biogen Inc. (BIIB) is a Top-Ranked Momentum Stock: Should You Buy?
|
|
Jun 24
|
TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union
|
|
Jun 19
|
Ionis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
|
|
Jun 14
|
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
|
|
Jun 14
|
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
|
|
Jun 13
|
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune
|
|
Jun 12
|
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab
|
|
Jun 11
|
Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower
|
|
Jun 11
|
FDA Advisers Like Lilly’s Alzheimer’s Drug. It’s Good News for Biogen.
|
|
Jun 11
|
Eli Lilly (LLY) Alzheimer's Drug Donanemab Gets FDA Panel Nod
|
|
Jun 11
|
Donanemab approval would fuel growth of amyloid-blocking Alzheimer’s drugs, analysts say
|
|
Jun 10
|
FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug
|
|
Jun 10
|
FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
|
|
Jun 10
|
Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance
|